ACP3 and cancer: Sipuleucel-T, an autologous dendritic cell targeting prostatic acid phosphatase (PAP) has improved survival for men with castration-resistant prostate cancer, is the first cancer vaccine approved by FDA in 2010 (Kantoff et al., 2010).